Harm Westdorp

1.5k total citations · 1 hit paper
43 papers, 696 citations indexed

About

Harm Westdorp is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Harm Westdorp has authored 43 papers receiving a total of 696 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 17 papers in Immunology. Recurrent topics in Harm Westdorp's work include Cancer Immunotherapy and Biomarkers (21 papers), Prostate Cancer Treatment and Research (15 papers) and Immunotherapy and Immune Responses (14 papers). Harm Westdorp is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Prostate Cancer Treatment and Research (15 papers) and Immunotherapy and Immune Responses (14 papers). Harm Westdorp collaborates with scholars based in Netherlands, United States and Germany. Harm Westdorp's co-authors include I. Jolanda M. de Vries, Gerty Schreibelt, Winald R. Gerritsen, Nicoline Hoogerbrugge, Carl G. Figdor, Niven Mehra, Sandra Heskamp, Marjolijn J. L. Ligtenberg, James Nagarajah and Bastiaan M. Privé and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Clinical Cancer Research.

In The Last Decade

Harm Westdorp

37 papers receiving 688 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies

2023 92 citations Bastiaan M. Privé, Steffie M. B. Peters et al. European Journal of Nuclear Medicine and Molecular Imaging profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harm Westdorp Netherlands	14	439	255	175	140	112	43	696
Rikke Løvendahl Eefsen Denmark	11	375 0.9×	165 0.6×	158 0.9×	82 0.6×	136 1.2×	32	624
Charles Schweizer United States	13	332 0.8×	157 0.6×	146 0.8×	208 1.5×	57 0.5×	24	703
Hoiseon Jeong South Korea	11	295 0.7×	115 0.5×	192 1.1×	90 0.6×	153 1.4×	24	552
Ivy X. Chen United States	8	560 1.3×	371 1.5×	238 1.4×	129 0.9×	131 1.2×	10	947
Cristina R. Ferrone United States	7	430 1.0×	184 0.7×	112 0.6×	112 0.8×	69 0.6×	12	609
Marissa S. Mattar United States	12	313 0.7×	153 0.6×	290 1.7×	230 1.6×	175 1.6×	22	666
Federico Sandoval France	9	777 1.8×	594 2.3×	306 1.7×	179 1.3×	147 1.3×	16	1.1k
W.E. Gillanders United States	5	826 1.9×	493 1.9×	231 1.3×	145 1.0×	133 1.2×	6	1.0k
Masato Sugano Japan	13	427 1.0×	135 0.5×	181 1.0×	236 1.7×	117 1.0×	44	709
Jeanne Thomassin‐Piana France	12	266 0.6×	251 1.0×	139 0.8×	170 1.2×	95 0.8×	43	798

Countries citing papers authored by Harm Westdorp

Since Specialization

Citations

This map shows the geographic impact of Harm Westdorp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harm Westdorp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harm Westdorp more than expected).

Fields of papers citing papers by Harm Westdorp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harm Westdorp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harm Westdorp. The network helps show where Harm Westdorp may publish in the future.

Co-authorship network of co-authors of Harm Westdorp

This figure shows the co-authorship network connecting the top 25 collaborators of Harm Westdorp. A scholar is included among the top collaborators of Harm Westdorp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harm Westdorp. Harm Westdorp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Braamse, Annemarie, Gijs Bleijenberg, Hanneke W.M. van Laarhoven, et al.. (2025). Cognitive Behavioral Therapy for Cancer‐Related Fatigue: A Comparison Between Patients Treated With Curative Intent and Patients With Advanced Cancer. Psycho-Oncology. 34(9). e70282–e70282. 1 indexed citations

Schreibelt, Gerty, Theo Boer, Jeanette M. Pots, et al.. (2025). NEOadjuvant Dendritic cell therapy added to first line standard of care in advanced epithelial Ovarian Cancer (NEODOC): protocol of a first-in-human, exploratory, single-centre phase I/II trial in the Netherlands. BMJ Open. 15(11). e102184–e102184. 1 indexed citations

Vliet, Hans van, Joeri A J Douma, Tanja D. de Gruijl, et al.. (2025). Exploring the effects of exercise on immune cell function and tumour infiltration in patients with breast cancer receiving neoadjuvant chemotherapy – a feasibility trial. Brain Behavior & Immunity - Health. 46. 101021–101021.

Wilpe, Sandra van, Martijn H. den Brok, Harm Westdorp, et al.. (2024). Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Annals of Oncology. 35(12). 1126–1137. 14 indexed citations

Privé, Bastiaan M., Maarten J. van der Doelen, James Nagarajah, et al.. (2024). Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 14(12). 4555–4569. 6 indexed citations

Schreibelt, Gerty, et al.. (2024). Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial. Frontiers in Immunology. 15. 1368103–1368103. 9 indexed citations

Privé, Bastiaan M., Steffie M. B. Peters, Yvonne H. W. Derks, et al.. (2023). Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. European Journal of Nuclear Medicine and Molecular Imaging. 50(7). 1906–1918. 92 indexed citations breakdown →

Tolmeijer, Sofie H., Sandra van Wilpe, Maartje J. Geerlings, et al.. (2023). Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer. European Urology Oncology. 7(2). 282–291. 10 indexed citations

Uijen, Maike J.M., Bastiaan M. Privé, Carla M.L. van Herpen, et al.. (2023). Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry. Nuclear Medicine Communications. 44(4). 270–275. 17 indexed citations

10.

Krens, Stefanie D., Neeltje Steeghs, Winette T.A. van der Graaf, et al.. (2023). Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients. Cancer Chemotherapy and Pharmacology. 93(4). 353–364. 3 indexed citations

11.

Janssen, Marcel J. R., Michiel Simons, Maarten J. van der Doelen, et al.. (2023). Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC. Clinical Genitourinary Cancer. 21(5). e352–e361. 1 indexed citations

12.

Bol, Kalijn F., Ellen Peeters, Carla M.L. van Herpen, Harm Westdorp, & Erik H.J.G. Aarntzen. (2023). Case Report: Imaging immune checkpoint inhibitor-induced yin-yang effects in the brain. Frontiers in Immunology. 14. 1199282–1199282. 2 indexed citations

13.

Oosterwijk, Egbert, et al.. (2022). Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment. Clinical Cancer Research. 28(17). 3652–3657. 40 indexed citations

14.

Kets, Marleen, et al.. (2022). 1391P Tumor-first mutation-specific risk approach to trigger germline testing in castration-resistant prostate cancer. Annals of Oncology. 33. S1179–S1179.

15.

Privé, Bastiaan M., Stijn Muselaers, Inge M. van Oort, et al.. (2022). An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. PubMed. 2. 863101–863101. 4 indexed citations

16.

Mehra, Niven, Gosse J. Adema, Linda G.W. Kerkmeijer, et al.. (2021). 642TiP Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer. Annals of Oncology. 32. S671–S671. 2 indexed citations

17.

Bloemendal, Martine, Winald R. Gerritsen, Carl G. Figdor, et al.. (2018). Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. Clinical & Translational Oncology. 21(6). 774–780. 6 indexed citations

18.

Westdorp, Harm, Sigrid Kolders, Nicoline Hoogerbrugge, et al.. (2017). Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Letters. 403. 159–164. 43 indexed citations

19.

Westdorp, Harm, Mark A.J. Gorris, Tanya M. Bisseling, et al.. (2016). Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers. Annals of Oncology. 27. vi362–vi362. 6 indexed citations

20.

Bekers, Elise M., Adriana C. H. van Engen–van Grunsven, Patricia J.T.A. Groenen, et al.. (2014). Metastatic melanoma mimicking solitary fibrous tumor: report of two cases. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 464(2). 247–251. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact